TrialBlood advances2020

Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.

Rudolf Benz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.